MICROBIOLOGY REAGENTSMolecular syndromic testing

With a high morbidity and mortality rate, ranging from 30% to 50%, sepsis and antimicrobial resistance pose a threat to global public health. Their treatment faces the challenge of increasing mechanisms of resistance, largely fuelled by the indiscriminate use of antibiotics. Accurate microbiological identification of the offending pathogens has become crucial for optimal treatment management. Response to treatment is directly linked to the time that elapses before appropriate antimicrobial therapy is administered.

In response to this critical public health challenge, Vitro has developed hybridisation reagents for molecular syndromic testing. Our kits allow bacteria, fungi and the most common antibiotic resistance genes to be detected in a single assay. Notably, it enables the direct analysis of clinical samples without the need to extract DNA, facilitating the process and enabling the efficient screening of infected and colonised patients for clinical management and infection control.

This innovative approach includes the detection of genes associated with multidrug-resistant Enterobacteriaceae (CRE, ESBL), vancomycin-resistant Enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). It is also important to note that our kit and detection method are patent-protected (patent no. WO2014102761A3).

Vitro is breaking new ground by providing antibiotic resistance results on the same day as a positive blood culture, significantly improving patient management and treatment.